Benutzer: Gast  Login
Titel:

The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.

Dokumenttyp:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Journal Article
Autor(en):
Chen, J; Röcken, C; Nitsche, B; Hosius, C; Gschaidmeier, H; Kahl, S; Malfertheiner, P; Ebert, MP
Abstract:
Imatinib targets KIT and platelet-derived growth factor receptors (PDGFR) and is highly effective in the treatment of CML and GIST patients. Pancreatic cancers express KIT and PDGFRs. Therefore, 26 patients with unresectable pancreatic cancer were randomized to either gemcitabine (1000 mg/m2 weekly) or imatinib (2x400 mg po) treatment daily. Pancreatic adenocarcinoma was confirmed histologically and expression of KIT and PDGFRbeta was determined immunohistochemically in the biopsy specimens. Qua...     »
Zeitschriftentitel:
Cancer Lett
Jahr:
2006
Band / Volume:
233
Heft / Issue:
2
Seitenangaben Beitrag:
328-37
Sprache:
eng
Volltext / DOI:
doi:10.1016/j.canlet.2005.03.027
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/15893416
Print-ISSN:
0304-3835
TUM Einrichtung:
II. Medizinische Klinik und Poliklinik (Gastroenterologie)
 BibTeX